CN103251631A - 用于治疗代谢性病症的水杨酸盐(酯)缀合物 - Google Patents

用于治疗代谢性病症的水杨酸盐(酯)缀合物 Download PDF

Info

Publication number
CN103251631A
CN103251631A CN2013101223642A CN201310122364A CN103251631A CN 103251631 A CN103251631 A CN 103251631A CN 2013101223642 A CN2013101223642 A CN 2013101223642A CN 201310122364 A CN201310122364 A CN 201310122364A CN 103251631 A CN103251631 A CN 103251631A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
formula
compound
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013101223642A
Other languages
English (en)
Chinese (zh)
Inventor
亚历克.梅因
卢克.马蒂克劳泽尔
埃里克.马约克斯
西尔维亚.加西亚维森特
马塔.塞拉诺穆诺兹
安东尼奥.佐尔扎诺奥拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmedica Therapeutics SL
Original Assignee
Genmedica Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmedica Therapeutics SL filed Critical Genmedica Therapeutics SL
Publication of CN103251631A publication Critical patent/CN103251631A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CN2013101223642A 2008-05-13 2009-05-13 用于治疗代谢性病症的水杨酸盐(酯)缀合物 Pending CN103251631A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5283908P 2008-05-13 2008-05-13
US61/052,839 2008-05-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801273287A Division CN102088965B (zh) 2008-05-13 2009-05-13 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用

Publications (1)

Publication Number Publication Date
CN103251631A true CN103251631A (zh) 2013-08-21

Family

ID=40827388

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013101223642A Pending CN103251631A (zh) 2008-05-13 2009-05-13 用于治疗代谢性病症的水杨酸盐(酯)缀合物
CN2009801273287A Expired - Fee Related CN102088965B (zh) 2008-05-13 2009-05-13 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801273287A Expired - Fee Related CN102088965B (zh) 2008-05-13 2009-05-13 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用

Country Status (8)

Country Link
US (2) US20090298923A1 (enExample)
EP (1) EP2291182A1 (enExample)
JP (1) JP5669729B2 (enExample)
CN (2) CN103251631A (enExample)
AU (1) AU2009248057B2 (enExample)
BR (1) BRPI0912716A2 (enExample)
CA (1) CA2724023C (enExample)
WO (1) WO2009138437A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
LT2315740T (lt) 2008-07-08 2018-02-26 Catabasis Pharmaceuticals, Inc. Acetilinti riebalų rūgščių salicilatai ir jų panaudojimas
EP2408443A1 (en) * 2009-03-16 2012-01-25 Genmedica Therapeutics SL Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2011044138A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Lipoic acid acylated salicylate derivatives and their uses
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US8440723B2 (en) * 2011-05-11 2013-05-14 Banavara L. Mylari Metformin salts of salicylic acid and its congeners
WO2013037984A1 (en) * 2011-09-16 2013-03-21 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US20150025006A1 (en) * 2011-09-16 2015-01-22 Genmedica Therapeutics Sl Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders
AU2019358595B2 (en) * 2018-10-11 2025-04-17 Basf As Aromatic compounds and pharmaceutical uses thereof
CN109761815A (zh) * 2019-02-26 2019-05-17 首都医科大学附属北京天坛医院 一种基于白藜芦醇治疗神经系统疾病的化合物及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080229A1 (en) * 1981-11-20 1983-06-01 Pietro Isnardi & C. Spa Salicylic derivatives of N-acetylcysteine
CN1523980A (zh) * 2000-12-07 2004-08-25 ��̹��ҽҩ��˾ 含有分散在基质中的活性物的药物制剂

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1583602A (en) * 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
IT1190987B (it) * 1982-09-07 1988-02-24 Pharma Edmond Srl Tioesteri dell'acido acetilsalicilico,procedimento per la loro preparazione e composizioni farmaceutiche che li conttengono
IT1206515B (it) * 1983-08-09 1989-04-27 Guidotti & C Spa Labor N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
US5948769A (en) * 1984-01-28 1999-09-07 Ismail; Roshdy Agent for treating heart diseases
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
JPH04217916A (ja) * 1990-06-21 1992-08-07 Japan Tobacco Inc 抗炎症剤
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
DE4444051A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US5871769A (en) * 1996-01-18 1999-02-16 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of diabetes mellitus
CA2265877A1 (en) * 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
PT1493439E (pt) * 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AUPO612397A0 (en) * 1997-04-11 1997-05-08 University Of Queensland, The Novel diflunisal esters and related compounds
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
WO1998051662A2 (en) * 1997-05-14 1998-11-19 Atherogenics, Inc. Compounds and methods for the inhibition of the expression of vcam-1
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5905090A (en) * 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US20020045580A1 (en) * 1999-11-24 2002-04-18 Sacks Meir S. Compositions for raising uric acid levels and methods of using same
US6258848B1 (en) * 1998-07-31 2001-07-10 Mount Sinai Hospital Methods and compositions for increasing insulin sensitivity
EP1113804A2 (en) * 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
JP2007326864A (ja) * 1999-01-20 2007-12-20 Takara Bio Inc 医薬組成物
AU2005300A (en) * 1999-01-20 2000-08-07 Takara Shuzo Co., Ltd. Medicinal compositions
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
WO2000076492A1 (en) * 1999-06-15 2000-12-21 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US20080213785A1 (en) * 2000-04-20 2008-09-04 Andrew Levy Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals
US20080044399A1 (en) * 2000-04-20 2008-02-21 Andrew Levy Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype
US20020037855A1 (en) * 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6355666B1 (en) * 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6365176B1 (en) * 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
IT1319201B1 (it) * 2000-10-12 2003-09-26 Nicox Sa Farmaci per il diabete.
AU2002230543A1 (en) * 2000-11-02 2002-05-15 Nutrition 21, Inc. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
JP4636780B2 (ja) * 2000-12-14 2011-02-23 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 真性糖尿病の検出および予防のための炎症性マーカー
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US7560442B2 (en) * 2001-04-30 2009-07-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Pharmaceutically active uridine esters
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
DE60224293T2 (de) * 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
JP4467429B2 (ja) * 2002-07-12 2010-05-26 アセロジエニクス・インコーポレイテツド 低溶解性プロブコールエステル類およびエーテル類の新規な塩形態
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2504329C (en) * 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US8093292B2 (en) * 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
MXPA02012315A (es) * 2002-12-13 2004-06-24 Univ Autonoma Metropolitana Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus.
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
AT500404A1 (de) * 2003-07-17 2005-12-15 Jsw Res Forschungslabor Gmbh Chemische verbindungen enthaltend tocopherol sowie zumindest einen weiteren pharmazeutischen wirkstoff
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US20070254055A1 (en) * 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
US7078064B2 (en) * 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
US20050143356A1 (en) * 2003-12-08 2005-06-30 Vanderbilt University Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy
EP1740196B1 (en) * 2004-03-23 2015-08-26 Lifeline Nutraceuticals Corporation Compositions and method for alleviating inflammation and oxidative stress in a mammal
WO2005112914A2 (en) * 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
EP1781267A4 (en) * 2004-05-17 2009-03-11 Combinatorx Inc METHOD AND REAGENTS FOR THE TREATMENT OF INFAMOUS DISEASES
CA2571683A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
EP1796681A2 (en) * 2004-08-02 2007-06-20 Genmedica Therapeutics SL Compounds for inhibiting copper-containing amine oxidases and uses thereof
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20070248705A1 (en) * 2004-10-22 2007-10-25 Kirin Beer Kabushiki Kaisha Agents for Activating the Transcription Factor Nrf2 and Foods Having Such Function
US20060099279A1 (en) * 2004-11-09 2006-05-11 Council Of Scientific & Industrial Research Novel anti-diabetic herbal formulation
SG144145A1 (en) * 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US20060166901A1 (en) * 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US8975227B2 (en) * 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US20070037865A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006311767A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
JP2009518415A (ja) * 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド 疾患の処置のための方法および組成物
CA2632607A1 (en) * 2005-12-09 2007-06-21 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7814420B2 (en) * 2005-12-14 2010-10-12 Honeywell International Inc. System and method for providing context sensitive help information
JP2007176799A (ja) * 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US20070231273A1 (en) * 2006-03-31 2007-10-04 Jie Wu Method for Decreasing Blood Glucose Levels
US20080015251A1 (en) * 2006-04-10 2008-01-17 Yissum Research Development Co., Of The Hebrew University Of Jerusalem Means and method for treating lipotoxicity and other metabolically related phenomena
US7629158B2 (en) * 2006-06-16 2009-12-08 The Procter & Gamble Company Cleaning and/or treatment compositions
WO2008027547A2 (en) * 2006-08-31 2008-03-06 The Brigham And Women's Hospital, Inc. Antioxidant therapies
US20080213319A1 (en) * 2006-10-06 2008-09-04 Hyun Kang Chemorepulsion of cells
US7498048B2 (en) * 2006-11-16 2009-03-03 Jose Angel Olalde Rangel Renal phyto-nutraceutical composition
EP2118279B1 (en) * 2007-01-16 2017-11-22 Ipintl, Llc Novel composition for treating metabolic syndrome
WO2009085695A1 (en) * 2007-12-31 2009-07-09 Horwitz Lawrence D Treatment or prevention of skin injury due to exposure to ultraviolet light
AU2010224867A1 (en) * 2009-03-16 2011-10-06 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080229A1 (en) * 1981-11-20 1983-06-01 Pietro Isnardi & C. Spa Salicylic derivatives of N-acetylcysteine
CN1523980A (zh) * 2000-12-07 2004-08-25 ��̹��ҽҩ��˾ 含有分散在基质中的活性物的药物制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIHAI G. NETEA 等: "The effect of salicylates on insulin sensitivity", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *

Also Published As

Publication number Publication date
AU2009248057A1 (en) 2009-11-19
JP2011520836A (ja) 2011-07-21
EP2291182A1 (en) 2011-03-09
CA2724023A1 (en) 2009-11-19
US20090298923A1 (en) 2009-12-03
AU2009248057B2 (en) 2013-02-21
US20130281413A1 (en) 2013-10-24
JP5669729B2 (ja) 2015-02-12
BRPI0912716A2 (pt) 2015-10-13
CN102088965A (zh) 2011-06-08
CN102088965B (zh) 2013-05-08
CA2724023C (en) 2014-02-18
WO2009138437A4 (en) 2010-03-04
WO2009138437A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
CN102088965B (zh) 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
CN102427809B (zh) 用于治疗代谢性疾病的抗炎剂和抗氧化剂轭合物
US20090069428A1 (en) Catalytic antioxidants and methods of use
JP2012520343A (ja) 代謝障害治療のための併用療法
EP2610242A1 (en) Positively charged water-soluble prodrugs of aspirin
EP2949344A2 (en) Use of intracellular enzymes for the release of covalently linked bioactives
WO2012115695A1 (en) Bis-fatty acid conjugates and their uses
CA2691446A1 (en) Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
EP2623495A1 (en) Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
AU2013206215C9 (en) Positively charged water-soluble prodrugs of aspirin
EP2751071A2 (en) Fatty acid amides, compositions and methods of use
US8466197B2 (en) Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
AU2013257708A1 (en) Compositions and methods for the treatment of diabetes
JP2015533114A (ja) 神経疾患の治療のための組成物及び方法
AU2013205946A1 (en) Salicylate conjugates useful for treating metabolic disorders
WO2013037984A1 (en) Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US20240382597A1 (en) Formulations of anti-inflammatory agents comprising msm with enhanced solubility in water

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130821